Essential drugs are those that satisfy the priority health care needs of the population. They are selected with due regard to public health relevance, evidence on efficacy and safety, and comparative cost-effectiveness. These medicines are intended to be available within the context of functioning health systems at all times in adequate amounts, in the appropriate dosage forms, with assured quality, and at a price the individual and the community can afford. The core concept rests on the idea that limited financial resources in developing countries are best spent on a carefully selected range of life-saving medicines rather than trying to stock every available pharmaceutical product on the market.
Before the concept of essential drugs emerged, many developing nations struggled with fragmented pharmaceutical markets flooded with thousands of unproven or redundant brand-name drugs. In 1975, the World Health Organization (WHO) Executive Board requested a report on the medical drug situation in developing countries. This led to the landmark WHO Expert Committee meeting in 1977, which compiled the first Model List of Essential Drugs containing about 200 active substances. This global shift transformed public health supply chains, proving that a limited list of standardized medications could drastically improve healthcare delivery while containing national drug expenditures.
Revising the model list is a continuous process. Committees review new scientific data, disease patterns, and emerging resistance profiles every two years to add breakthrough treatments or remove obsolete ones.
Adopting an essential medicines framework streamlines every level of health service delivery. Procurement officers can bulk-purchase fewer distinct items, securing lower prices through economies of scale. Healthcare workers benefit because mastering a smaller pharmacopoeia reduces prescribing errors and simplifies clinical training. Patients experience improved drug availability since clinics rarely run out of core supplies. Furthermore, supply chain management, storage, and inventory tracking become much simpler for pharmacists and nurses working in rural health posts.
Despite clear benefits, implementing essential drug lists encounters persistent obstacles. Bureaucratic delays in procurement often trigger severe stock-outs at primary healthcare facilities. In many regions, poor storage infrastructure compromises the stability of heat-sensitive biologicals and antibiotics. Counterfeit and substandard drugs frequently infiltrate public and private supply chains due to weak regulatory enforcement. Additionally, rigid lists can sometimes lag behind rapid epidemiological transitions, failing to address emerging chronic non-communicable diseases quickly enough.
The National Drug Policy (NDP) of Nigeria heavily integrates the essential drugs concept to guarantee equitable healthcare delivery. The policy guides the compilation and regular revision of the Nigeria Essential Medicines List (EML), which dictates what drugs can be procured for federal, state, and local government health facilities. It also promotes local pharmaceutical manufacturing of these priority items to reduce national dependence on costly importation. For Nigerian nurses, understanding this policy clarifies drug availability trends, prescription guidelines, and the regulatory framework governing safe patient care across primary, secondary, and tertiary settings.